Acorda Buys Its Way Into A Parkinson's Franchise
This article was originally published in The Pink Sheet Daily
Having acquired Parkinson's candidate CVT-301 in the 2014 purchase of Civitas, Acorda sees Biotie's Phase III tozadenant as an ideal candidate to create a complementary Parkinson's disease franchise.
You may also be interested in...
Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout
Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.
Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
Travere Looks Ahead To Phase III In Homocystinuria
The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.